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On July 9th 2019, WHO updated it’s ‘Model List of Essential Medicines’ to include oral 
ivermectin for ectoparasitic infections.1 This recommendation follows the 2017 WHO 
categorization of scabies as a Neglected Tropical Disease. The list covers the ‘minimum 
medicine needs for a basic health-care system, listing the most efficacious, safe and cost–
effective medicines for priority conditions’.1 In the UK scabies outbreaks remain a significant 
public health burden in care homes for elderly people.2 Yet this essential, and safe, medicine 
remains unlicenced for scabies treatment in the UK, and is only available through specialist 
importers. Standard treatment consists of topical acaracides, applied over the whole body 
same day to all residents and staff, left on usually overnight before showering, and repeated 
seven days later. This is labour intensive and can be distressing, especially for residents with 
dementia who may not understand why it is happening.2 Unsurprisingly crusted scabies cases 
(often present in these outbreaks) can be resistant to topical treatment due to the barrier of 
hyperkeratotic skin crusts. This vulnerable population, often at the end of life, deserves 
better.  
 
Unfortunately, ill-founded safety concerns about ivermectin use in the elderly still deter 
clinician use, arising from a 1997 letter3 published in The Lancet. The authors reported 
increased mortality in a group of 47 long-term health facility residents (the majority with 
dementia) treated with oral ivermectin for scabies compared to retrospective, inadequately 
matched controls. Potential confounding was acknowledged but the authors still advised 
against ivermectin use in the elderly. The letter was criticised at the time for methodological 
errors, and data presented from other outbreaks did not demonstrate an association between 
ivermectin and mortality.4 Mass Drug Administrations have since been conducted across the 
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world. Recent modelling work re-analysed the letter’s data, showing it did not conclusively 
demonstrate ivermectin caused excess mortality.5 Yet despite all this, twenty-two years after 
the letter was published, elderly people in the UK experiencing distressing outbreaks of a 
Neglected Tropical Disease are still deprived access to an effective treatment that’s relative 
ease of administration would allow greater dignity in care.  
 
In line with WHO we call for steps to enable access to this essential medicine, and we 
recommend its wider use for scabies by UK clinicians. We also urge The Lancet to place an 
editorial warning on the 1997 letter, pointing to the WHO endorsed status of ivermectin 
treatment for ectoparasitic infections, and stating the report was flawed. 
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